Edgar Filing: Dentzer James E - Form 4

Dentzer Jame	es E											
Form 4												
February 05,	2008											
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION									OMB AF	PROVAL		
	UNITE	D STATES					NGE C	COMMISSION	OMB	2025 0.097		
	• •		Was	shington,	D.C. 20	549			Number:	3235-0287		
Check thi if no long	ter								Expires:	January 31,		
subject to		EMENT O	F CHAN	GES IN	BENEFI	CIA	L OW	NERSHIP OF	Estimated a	2005 Verage		
Section 1				SECURITIES					burden hours per			
Form 4 or	r								response	0.5		
Form 5	Filed p	oursuant to S	Section 1	6(a) of the	e Securit	ies E	xchang	e Act of 1934,				
obligation may cont					-			1935 or Section	n			
See Instru		30(h)	of the In	vestment	Compan	y Ac	t of 194	0				
1(b).												
(Print or Type F	Responses)											
		D *						5 5 1 1. 6				
1. Name and A Dentzer Jam	ddress of Reporting	ng Person _		er Name and Ticker or Trading				5. Relationship of Reporting Person(s) to Issuer				
Dentzer Jahr	IES E		Symbol			a a 1		135001				
				MICUS THERAPEUTICS INC				(Check all applicable)				
			[FOLD]					× ×	11	, 		
(Last)	(First)	(Middle)	3. Date of	Earliest Tr	ansaction			Director		Owner		
(Month/				onth/Day/Year)				X_ Officer (give title Other (specify below) below)				
	JS THERAPE		02/01/2	008				/	Financial Office	er		
INC., 6 CEI	DAR BROOK	DRIVE										
	(Street)		4. If Ame	4. If Amendment, Date Original				6. Individual or Joint/Group Filing(Check				
Filed(Mo			Filed(Mor	nth/Day/Year)			Applicable Line)				
						X Form filed by One Reporting Person Form filed by More than One Reporting						
CRANBUR	Y, NJ 08512							Person	fore than One Ke	porting		
(City)	(State)	(Zip)		T N D	•	~	•.•					
-		-		e I - Non-D				uired, Disposed of		-		
1.Title of	2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if			3.	4. Securit			5. Amount of	6. Ownership			
Security (Instr. 3)	(Month/Day/Yea	/	n Date, 11	Transactic Code		•		Securities Beneficially	Form: Direct (D) or	Beneficial		
(Insu. 5)		any (Month/I	Day/Year)					Owned	Indirect (I)			
		(1.101111)	<i>suj, 1011)</i>	(1115411-0)				Following	(Instr. 4)	(Instr. 4)		
						(A)		Reported				
						(A) or		Transaction(s)				
				Code V	Amount	(D)	Price	(Instr. 3 and 4)				
Common	02/01/2008			F	220 (1)	D	\$	36,475	D			
Stock	02/01/2000			1	220	D	10.24	50,175				

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Dentzer James E - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	ınt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address		Relationships							
		Director	10% Owner	Officer	Other				
Dentzer James E C/O AMICUS THERAPEUTICS INC. 6 CEDAR BROOK DRIVE CRANBURY, NJ 08512				Chief Financial Officer					
Signatures									
/s/ James E.									
Dentzer 02/0	5/2008								
<u>**</u> Signature of	Date								

**Signature of Reporting Person

.....

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

In order to comply with the minimum statutory federal tax withholding rate of 25% plus 1.45% for Medicare, the reporting person

(1) surrendered a portion of the vested shares, representing 26.45% of the total value of the shares then vested, to the issuer in connection with its withholding obligations. The restricted stock award to which this disclosure applies vests in a series of monthly installments as outlined in the stock award agreement previously filed on 4/27/2007.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.